Evidence map›Paper›PMID 38492111›Full record

ReviewWorld journal of urology2024

Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer.

John Nikitas, Amar Kishan, Albert Chang, Sai Duriseti, Nicholas G Nichols, Robert Reiter, Matthew Rettig, Wayne Brisbane, Michael L Steinberg, Luca Valle

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

John NikitasDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA.
Amar KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA.
Albert ChangDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA.
Sai DurisetiDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA.
Nicholas G NicholsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA.
Robert ReiterDepartment of Urology, University of California, Los Angeles, Los Angeles, USA.
Matthew RettigDepartment of Urology, University of California, Los Angeles, Los Angeles, USA.
Wayne BrisbaneDepartment of Urology, University of California, Los Angeles, Los Angeles, USA.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, USA.
Luca ValleRadiation Oncology Service, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, USA. LFValle@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-5781-4174
University of California, Los Angeles · USLos Angeles Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTreatment intensification of external beam radiotherapy (EBRT) plays a crucial role in the treatment of high-risk prostate cancer.

methodsWe performed a critical narrative review of the relevant literature and present new developments in evidence-based treatment intensification strategies.

resultsFor men with high-risk prostate cancer, there is strong evidence to support prolonging androgen deprivation therapy (ADT) to 18-36 months and escalating the dose to the prostate using a brachytherapy boost. A potentially less toxic alternative to a brachytherapy boost is delivering a focal boost to dominant intraprostatic lesions using EBRT. In patients who meet STAMPEDE high-risk criteria, there is evidence to support adding a second-generation anti-androgen agent, such as abiraterone acetate, to long-term ADT. Elective pelvic lymph node irradiation may be beneficial in select patients, though more prospective data is needed to elucidate the group of patients who may benefit the most. Tumor genomic classifier (GC) testing and advanced molecular imaging will likely play a role in improving patient selection for treatment intensification as well as contribute to the evolution of treatment intensification strategies for future patients.

conclusionTreatment intensification using a combination of EBRT, advanced hormonal therapies, and brachytherapy may improve patient outcomes and survival in men with high-risk prostate cancer. Shared decision-making between patients and multidisciplinary teams of radiation oncologists, urologists, and medical oncologists is essential for personalizing care in this setting and deciding which strategies make sense for individual patients.

Indexed as

BrachytherapyProstatic NeoplasmsAndrogen AntagonistsCombined Modality TherapyHumansMaleProspective StudiesRadiotherapyAndrogen AntagonistsAndrogen deprivation therapyHigh-riskProstate cancerRadiotherapyTreatment intensification

Identifiers

PMID38492111
OpenAlexW4392878369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.